DnB Asset Management
PCVX icon

DnB Asset Management’s Vaxcyte PCVX Stock Holding History

DnB Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
18,041
-1,059
-6% -$57.5K ﹤0.01% 640
2026
Q1 		$1.11M Buy
19,100
+2,629
+16% +$143K ﹤0.01% 633
2025
Q4 		$760K Buy
16,471
+5,235
+47% +$234K ﹤0.01% 657
2025
Q3 		$405K Sell
11,236
-5,519
-33% -$183K ﹤0.01% 679
2025
Q2 		$545K Buy
16,755
+6,924
+70% +$227K ﹤0.01% 645
2025
Q1 		$371K Buy
9,831
+2,764
+39% +$221K ﹤0.01% 679
2024
Q4 		$579K Buy
7,067
+1,255
+22% +$125K ﹤0.01% 652
2024
Q3 		$664K Buy
+5,812
New +$524K ﹤0.01% 645

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

DnB Asset Management's PCVX Position: Q2 2026 in Review

DnB Asset Management reduced its Vaxcyte (PCVX) stake by 5.5% in Q2 2026, selling an estimated $57.5K and leaving 18,041 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #640.

DnB Asset Management first reported a position in PCVX in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.11M in Q1 2026. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • DnB Asset Management held 18,041 shares of Vaxcyte worth $1.05M as of Q2 2026.
  • DnB Asset Management sold 1,059 Vaxcyte shares in Q2 2026, an estimated $57.5K.
  • Vaxcyte made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #640 holding.
  • DnB Asset Management first reported a position in Vaxcyte in Q3 2024 and has held it in 8 quarters since.
  • DnB Asset Management's Vaxcyte position peaked at $1.11M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.